Amedisys, Inc. (AMED) Thwomps Q2 Profit Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Amedisys (AMED) Moves to Highs of Session Following Better-than-Expected Results
July 30, 2014 12:22 PM EDTAmedisys (NASDAQ: AMED) is gaining momentum amid today's stronger-than-expected Q2 results. Shares are now up 17% on heavy volume.
Amedisys, Inc. (NASDAQ: AMED) reported Q2 EPS of $0.25, $0.21 better than the analyst estimate of $0.04. Revenue for the quarter came in at $305... More



